Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-11
2007-09-11
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S070000, C544S125000, C514S232800, C514S232500
Reexamination Certificate
active
10963293
ABSTRACT:
The invention provides novel classes of Isoquinoline Derivatives. Pharmaceutical compositions and methods of making and using the compounds, are also described.
REFERENCES:
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 4113731 (1978-09-01), Winters et al.
patent: 4263304 (1981-04-01), Ishizumi et al.
patent: 5079246 (1992-01-01), Forbes et al.
patent: 5260316 (1993-11-01), Van Duzer et al.
patent: 5262564 (1993-11-01), Kun et al.
patent: 5597831 (1997-01-01), Michalsky et al.
patent: 5710162 (1998-01-01), Okazaki et al.
patent: 5733918 (1998-03-01), Okazaki et al.
patent: 6028079 (2000-02-01), Okazaki et al.
patent: 6346535 (2002-02-01), Cotter et al.
patent: 6346536 (2002-02-01), Li et al.
patent: 6498194 (2002-12-01), Cotter et al.
patent: 6635642 (2003-10-01), Jackson et al.
patent: 6828319 (2004-12-01), Jagtap et al.
patent: 6956035 (2005-10-01), Jagtap et al.
patent: 2002/0099063 (2002-07-01), Cotter et al.
patent: 2003/0096833 (2003-05-01), Jagtap et al.
patent: 2004/0039009 (2004-02-01), Jagtap et al.
patent: 2349227 (2000-05-01), None
patent: 2025932 (1980-01-01), None
patent: 2003267888 (2003-09-01), None
patent: WO93/05023 (1993-03-01), None
patent: WO99/08680 (1999-02-01), None
patent: WO99/11311 (1999-03-01), None
patent: WO99/11623 (1999-03-01), None
patent: WO99/11628 (1999-03-01), None
patent: WO99/11644 (1999-03-01), None
patent: WO99/11645 (1999-03-01), None
patent: WO99/11649 (1999-03-01), None
patent: WO99/59973 (1999-11-01), None
patent: WO99/59975 (1999-11-01), None
patent: WO 00/21537 (2000-04-01), None
patent: WO 00/39070 (2000-07-01), None
patent: WO 00/39104 (2000-07-01), None
patent: WO 00/42040 (2000-07-01), None
patent: WO 01/12199 (2001-02-01), None
patent: 01/90077 (2001-11-01), None
patent: WO 02/26284 (2002-01-01), None
patent: WO-04/014862 (2004-02-01), None
patent: 2005/012524 (2005-02-01), None
patent: 2005/053662 (2005-06-01), None
Aldrich, p. 32, Aldrich Chemical Company, 1992.
Bloch et al., The role of the 5′-hydroxyl group of adenosine in determining substrate specificity for adenosine deaminase, J. Med. Chem., 10(5):908-912, 1967.
Burger's Medicinal Chemistry and Drug Discovery, 5thed., vol. 1:Principles and Practice, John Wiley and Sons, Inc., pp. 975-977, 1994.
Hakimelahi et al., Ring Open Analogues of Adenine Nucleoside, Aminoacyl Derivatives of Cyclo-and Acyclo-nucleosides, Helvetica Chemica Acta, 70:219-231, 1987.
Hiremath et al., A New Method for the Synthesis of 6H, 11H-Indolo[3,2-c]-isoquinolin-5-ones/thiones and their Reactions, J. Heterocyc. Chem., 30(3):603-609, 1993.
Kawana et al., Nucleoside Peptides. III. The Synthesis of N-[1-(9-Adenyl)-β-D-ribofuranuronosyl] Derivatives of Certain Amino Acids and Peptides, J. Org. Chem., 37(2):288-290, 1972.
Mandir et al., A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism, J. Neurochem., 83(1):186-192, 2002.
Mandir et al., Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism, Proc. Natl. Acad. Sci. U.S.A., 96(10):5774-5779, 1999.
Ojika et al, Ptaquiloside, a Potent Carcinogen Isolated From Bracken Fem Pteridium Aquilinum Var. Latiusculum: Structure Elucidation Based On Chemical and Spectral Evidence, and Reactions with Amino Acids, Nucleosides, and Nucleotides, Tetrahedron, 43(22):5261-5274, 1987.
Wang et al., Apoptosis inducing factor and PARP-mediated injury in the MPTP mouse model of Parkinson's disease, Ann N.Y. Acad. Sci., 991:132-139, 2003.
Yamaguchi et al., The Synthesis of Benzofuroquinolines. IX. A Benzofuroisoquinolinone and a Benzofuroisocoumarin, J. Hetercycl. Chem., 32(2):419-423, 1995.
Abdelkarim et al., Protective effects of PJ34, a novel, potent inibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke, Int. J. Mol. Med., 7:255-260, 2001.
Ando et al., Cyclization reactions of 1,2-bis(2-cyanophenyl—propionitriles. II. Synthesis of 5-amino-4,7-dimethoxy-11H-indo[1,2-c]isoquinolin-11-one, Bull. Chem. Soc. Japan, 47:1014-17, 1974.
Banasik et al., Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase, J. Biol. Chem., 267:1569-75, 1992.
Banasik et al., Inhibitors and activators of ADP-ribosylation reactions, Mol. Cell. Biochem., 138:185-97, 1994.
Chatterjea et al., Cyclisation of alpha-benzylhomophthalic acids, Experientia, 16:439-440, 1960.
Chatterjea et al., On 4-Keto-3:4-Dihydrolsocoumarin, J. Indian Chem. Soc. 44(11):911-919, 1967.
Cushman et al., Synthesis of new indeno[1,2b]isoquinolines: Cytotoxic non-camptothecin topoisomerase I inhibitors, J. Med. Chem., 43(20):3688-3698, 2000.
Dusemund et al., 5-hydroxyisoindolo[2,1b]isoquinotin-7-one: Synthesis and isomerization, Arch. Pharm (Weinheim, Ger.), 317:381-2, 1984.
Griffin et al., Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP), J. Med. Chem., 41:5247-5256, 1998.
Grupp et al., Protection against hypoxia-reoxygenation in the absence of poly9ADP-ribose) synthetase in isolated working hearts, J. Mol. Cell Cardiol., 31:297-303, 1999.
Hiremath et al., Synthesis of Substituted 7H-Indolo[2,3-c] isoquinolines, Indian Journal of Chemistry, Section B 24B(12):1235-1238, 1985.
Hiremath et al., Synthesis and Biological Evaluation of Some Substituted 5H, 6H, 7H,-Indolo[2,3-C] Isoquinolin-5-thiones and their Derivatives, Indian Journal of Heterocyclic Chemistry 3(1):37-42, 1993.
Hiremath et al., Synthesis of [10-substituted-6H,7H-indolo[2,3-c]iso-quinolin-5-one-6-yl]acetyl-3,5-disubstituted-pyrazoles/pryazolones and 5-[10-substituted-6H,7H-indolo[2,3-c]iso-quinolin-5-one-6-yl]methyl-1,3,4-oxadiazol-2-thiones, Journal of the Indian Chemical Society 72(10):735-738, 1995.
Hiremath et al., Synthesis and Biological Studies of Some New Brideghead Nitrogen Heterocycles Containing Indoloisoquinoline Nucleus, Oriental Journal of Chemistry 13(2):173-176, 1997.
Hiremath et al., Synthesis of substituted 2-(5-oxo/thioxo-1,3,4-oxadiazol-2-yl)-indoles & 2-(5-oxo/thioxo-1,3,4-oxadiazol-2-ylamino)indoles, Indian Journal of Chemistry, Section B 22B(6):571-576, 1983.
Jantzen and Robinson, Modern Pharmaceutics, 3rded., eds. Baker and Rhodes, p. 596, 1995.
Jha et al., Synthesis of Indeno[2,1-c] isocoumarins and indeno[2,1-c]isoquinolones, Indian Journal of Chemistry, Section B 24B(4):440-444, 1985.
Kirby et al., Hydride hyperconjugation in 1(3)-methylazulenes, Tetrahedron Lett., 27:1-4, 1960.
Kirby et al., 4,6,8-trimethylazulenium percholrate, Chemistry & Industry (London, UK), 1217-1218, 1960.
Lal et al., Applications of carbon-nitrogen bond cleavage reaction: A synthesis/derivisation of 11H-indeno[1,2-c]isoquinolones, Indian J. Chem., Sect. B, 38B:33-39, 1999.
Lamping et al., LPS—binding protein protects mice from septic shock caused by LPS or gram-negative bacteria, J. Clin. Invest., 101(10):2065-2071, 1998.
Mabley et al., Inhibition of poly(ADP-ribose) synthetase by gene disruption or inhibitin with 5-iodo-6-amino-1,2-benzopyrone protects mice from multiple-low-dose-streptozotocin-induced diabetes, Br. J. Pharmacol., 133(6):909-919, 2001.
Milam et al., Inhibitors of poly(adenosine diphosphate-ribose) synthesis: effect on other metabolic processes. Science, 223:589-591, 1984.
Morrison and Boyd, Organic Chemistry, 5thed., Allyn and Bacon, Inc., p. 179, 1987.
Ohno et al., Modulation of adenosine receptor affinity and intrinsic efficacy in adenine nucleosides substituted at the 2 position, Biorg. Med. Chem., 12:2995-3007, 2004.
Parrillo, Pathogenic mechanisms of septic shock, N. Eng. J. Med., 328:1471-1477, 1993.
Shinkwin et al., Synthesis of thiophenecarboxamides, thieno[3,4-c]pyridin-4(5H)-ones and thieno[3,4-d]pyrimidin-4(3H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP). Bioorg. Med. Chem., 7:297-308, 1999.
Soriano et al., Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nature Medicine, 7(1):108-113, 2001.
Southan and Szabo, Poly(ADP-ribose) polymerase inhibitor
Jagtap Prakash
Roy Aloka
Salzman Andrew L.
Szabo Csaba
Williams William
Aulakh Charanjit S.
Inotek Pharmaceuticals Corporation
Wilmer Cutler Pickering Hale and Dorr LLP
LandOfFree
Isoquinoline derivatives and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isoquinoline derivatives and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isoquinoline derivatives and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3777873